FAST NEWS: CStone Submits New Drug Application, Grants Restricted Shares to Non-Executive Director
The latest: CStone Pharmaceuticals (2616.HK) announced it has reached the primary endpoint of its clinical study for its drug Cejemly to treat relapsed or refractory T-cell lymphoma, and plans to…
CStone Revs Up for Big Growth With New Drug Approval
Company says China has approved its latest cancer drug, which it is commercializing with global pharmaceutical giant Pfizer Key takeaways: CStone announced its monoclonal antibody drug Cejemly has been approved…
RELATED ARTICLES
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK -
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
2616.HK
